Giving monkeys two powerful anti-HIV antibodies immediately after infection with an HIV-like virus enabled the immune systems of some of the animals to control the virus long after the antibodies were gone.
Three broadly neutralizing antibodies in an HIV-positive person may explain how this individual controlled HIV for 30 years without antiretroviral therapy.
A first-in-class HIV-1 capsid inhibitor interrupts replication at two steps of the viral lifecycle and has pharmacokinetic properties that may permit once-monthly or less frequent dosing.
Two new monoclonal antibodies demonstrated success in helping people living with HIV suppress their viral loads to undetectable levels.
A new analysis reports that HIV-positive women in clinical trials in sub-Saharan Africa are likely to get pregnant as often as those receiving care outside of research settings.
Two doses of a therapeutic HIV vaccine plus three infusions of romidepsin, an HIV latency reactivator, allowed five of 13 trial participants to stay off antiretroviral therapy without rebound for up to 28 weeks in a Spanish proof-of-concept study....
Paul Sax, M.D., discusses the clinical importance of new drugs in development highlighted at CROI 2017 -- and about what else is on the near horizon when it comes to antiretroviral therapies for HIV.
A CROI 2017 poster presented in vitro results of an NRTI compound from Gilead that appears has been in preclinical development for at least a decade.
NIH scientists have found that the presence of the protein alpha-4 beta-7 integrin on the surface of HIV and SIV may help explain why an antibody protected monkeys from SIV in previous experiments.
Two oral presentations on a new integrase inhibitor bictegravir were included in the first session at CROI 2017 looking at new treatment and treatment strategies.